Summit Therapeutics Inc. SMMT
New risk paragraphs, branching off last year
Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Feb 24, 2025. A box jumps to the paragraph as filed, below.
Paragraphs with nothing like them in last year's 10-K
24 paragraphs in Risk Factors of the 10-K filed Feb 23, 2026 with nothing like them in the 10-K filed Feb 24, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
In January 2026, the FDA accepted for filing our BLA seeking approval of ivonescimab in combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC post-TKI therapy and provided a PDUFA target action date of November 14, 2026. The delay or denial of regulatory approval, inability to maintain regulatory approval, inability to complete post-marketing requirements, or the requirement to resubmit any marketing application with additional data or information could mean that we otherwise negatively would delay commercialization of ivonescimab and adversely impact our ability to generate revenue, our business and our operations.
this setting. If the FDA does not agree with our analysis of the HARMONi data, they may delay or deny regulatory approval in this proposed indication, require us to resubmit the marketing application with additional data or information, or take other actions that could delay commercialization of ivonescimab and adversely impact our ability to generate revenue, our business and our operations. We cannot predict the results of our ongoing or future clinical trials.
Regulatory authorities have substantial discretion in the approval process. They may refuse to accept any application or may decide that our data are insufficient for approval and require additional clinical trials or other studies. In our public communications, we may designate certain of our clinical trials as “pivotal” if we believe that these clinical trials, if successful, will support BLA submissions; however, there can be no assurance that any clinical trial that we designate as “pivotal” will be viewed as sufficient by the FDA, the EMA and other comparable regulatory authorities in other jurisdictions to support regulatory approval. If we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated, we may incur significant additional costs and regulatory approval may be delayed or prevented.
There can be no guarantee that the FDA or other regulatory authorities will interpret the results or reach the same conclusions from the data as we do, or fully agree that our development plans are sufficient for submission or approval of a BLA. In the event that the FDA requires us to conduct clinical trials with more patients than planned, to conduct clinical trials with designs or endpoints other than we currently anticipate, we may not have the funding to enlarge or conduct such trials and we may not be able to raise sufficient funding to do so, which could delay or prevent commercialization of our product candidates. In addition, the FDA or other regulatory authorities may change their views on aspects of the clinical programs, including clinical trial designs, or the ability of the trials as designed to support approval of a product. If we are unable to effectively and efficiently resolve and comply with the inquiries and requests of the FDA and other comparable international regulatory authorities, the approval of our product candidates may be delayed, which could delay or prevent commercialization of our product candidates.
•data privacy or other laws being implemented that restrict transfer of patient data from one country to another.
We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. We are currently conducting clinical trials in China, and we expect to continue to conduct trials internationally in the future. The acceptance of data from clinical trials conducted outside the United States by the FDA or other regulatory authorities may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for regulatory approval in the United States, the FDA will generally not approve the application unless (i) the data are applicable to the U.S. population and U.S. medical practice and (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations, and the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCPs and the FDA is able to validate the data from the study through an
onsite inspection if deemed necessary. Additionally, the FDA’s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with foreign exchange fluctuations, compliance with foreign manufacturing, customs, shipment and storage requirements, and cultural differences in medical practice and clinical research, and diminished protection of intellectual property in some countries.
There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. For example, for FDA acceptance, we will have to demonstrate that the foreign data are applicable to the U.S. population and U.S. medical practice. If the FDA or other regulatory authorities do not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in current or future product candidates that we may develop being delayed or not receiving approval for commercialization in the applicable jurisdiction.
•Inability to build a marketing operations infrastructure with the development of advance analytics allowing for different channels to be utilized for promotions beyond the sales organization
Show the other 11
•Lack of appropriate guidelines, pathways, and formulary placement for reimbursement;
Evolving competition with new products or existing products with new data or combinations which may confer efficacy or safety advantages.
The manufacturing process for a product candidate is subject to FDA and other foreign regulatory authority review. We, and our suppliers and manufacturers, must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory requirements, such as cGMP. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the FDA and other foreign regulatory authorities. If our contract manufacturers are unable to maintain a compliance status acceptable to the FDA and other foreign regulatory authorities, our product candidates may not be approved. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, we may not be able to rely on their manufacturing facilities for the manufacture of components of any product candidates. Moreover, although we do not control the manufacturing process at our contract manufacturers and are completely dependent on them for compliance with current regulatory requirements, we are nonetheless responsible for ensuring that any product candidates are manufactured in accordance with applicable laws and regulatory requirements. In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all.
the use of our products compared to current alternatives and do so to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained and in what time frame.
In addition, third-party payors, whether domestic or foreign, governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to healthcare systems that could impact our ability to sell our product candidates, if approved, profitably. There have been, and likely will continue to be, legislative and regulatory proposals at the federal and state levels directed at broadening the availability of, and containing or lowering the cost of, healthcare. The implementation of cost containment measures that third-party payors and healthcare providers are instituting and any other healthcare reforms may prevent us from being able to generate, or may reduce, our revenues from the sale of our product candidates, if approved, and our product candidates may not be profitable. Such reforms could have an adverse effect on anticipated revenue from product candidates for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.
•changes in U.S. law regarding data security and providing sensitive personal data to China; and
In addition, certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting the supply of material to us. For example, the BIOSECURE Act, which was recently signed into law in December 2025, prohibits U.S. federal agencies from entering into or renewing any contract with any entity that uses biotechnology equipment or services produced or provided by a “biotechnology company of concern” to perform that contract as well as authorizes the U.S. government to name additional Chinese “biotechnology companies of concern.” While prior versions of the BIOSECURE Act explicitly named “biotechnology companies of concern,” the revised version defines a “biotechnology company of concern” as an entity that is identified on the annual 1260H List of Chinese military companies (the “1260H List”) issued by the U.S. Department of Defense, any entity designated by the U.S. Government as such, and certain affiliates of the foregoing. If this law, or similar laws that may be enacted, impact Chinese biotechnology manufacturing companies that are or may become contractors or subcontractors of ours or provide biotechnology equipment or services in the manufacture of our products or products candidates, we may be restricted in our ability to work with such Chinese biotechnology manufacturing companies to the extent we would contract with, or otherwise receive funding from, the U.S. government, or work with sites or institutions that may receive funding from the U.S. government. As a result, we may need to seek alternative contract manufacturer relationships. While we believe we will be able to identify and contract with such alternative contract manufacturers, we cannot predict the terms of any such alternative arrangement nor what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by China or the other countries in retaliation.
Changes to tax laws in the US, UK, and other countries, as well as new or increased taxes or fees, could raise our future tax liabilities and negatively impact our operating results and cash flows. Recent US tax reforms, such as the IRA and the One Big Beautiful Bill Act (“OBBBA”), have introduced significant changes to corporate taxation, including new rules for interest deductions, research and development expenses, and stock repurchases. The OBBBA, signed into law on July 4, 2025, has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. In the UK, updates to the research and development tax regime may reduce the cash benefits we receive, especially for spending outside the UK, and further changes are expected as the government considers merging existing research and development schemes. The interpretation and implementation of these laws may change, and any new legislation or guidance could affect our tax rates, increase compliance costs, and have an adverse effect on our financial position.
Other legislative changes have been proposed and adopted since passage of the ACA. These have, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers. For example, several healthcare reform initiatives culminated in the enactment of the IRA, which includes several provisions to lower prescription drug costs for Medicare patients and reduce drug spending by the federal government. Among other things, the IRA requires HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that the U.S. Centers for Medicare and Medicaid Services (“CMS”) reimburses under Medicare Part B and Part D. Negotiations will occur for high expenditure single-source biological products that have been on the market for 11 years (seven years for single-source drugs). Revised prices will take effect two years after these negotiations occur. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D products in 2023, negotiations began in 2024, and the negotiated price for each product has been announced. In addition, CMS has selected and announced the negotiated price for 15 additional Medicare Part D drugs which will become effective in 2027. For 2028, an additional 15 drugs, which may be covered under either Medicare Part B or Part D, the negotiated price will be effective, and for 2029 and subsequent years, 20
Part B or D drug negotiated prices will be effective. The negotiated prices have represented, and will continue to represent, a significant discount from average prices to wholesalers and direct purchasers.
The IRA also imposes rebates on Medicare Part B and Part D drugs whose prices have increased at a rate greater than the rate of inflation, and in 2024, CMS finalized regulations for the Medicare Part B and Part D inflation rebates. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties.
The current administration is pursuing policies to reduce regulations and expenditures across government including at HHS, which include the FDA and CMS, and related agencies. For example, on May 12, 2025, President Trump issued an Executive Order that, among other things, required HHS, within 30 days, to establish and communicate to drug manufacturers MFN price targets designed to bring drug prices for American patients in line with those in comparably developed nations. If significant progress towards MFN pricing is not achieved, the Executive Order requires HHS to propose a rulemaking to implement MFN pricing. Recently, on December 23, 2025, CMS issued proposed regulations to establish, under the Center for Medicare and Medicaid Innovation, two mandatory MFN demonstration models under Medicare Parts B and D, respectively. If these rules or other MFN pricing rules are finalized, they are likely to reduce prices of at least some drugs in the United States, if they are also sold in comparator countries. Even if we do not market drugs in such countries, we will be indirectly affected if our drugs competed with drugs whose prices were reduced as a result of MFN pricing initiatives.
On April 8, 2025, the U.S. Department of Justice implemented a final rule carrying out Executive Order 14117, “Preventing Access to U.S. Sensitive Personal Data and Government-Related Data by Countries of Concern or Covered Persons (the “Rule”), which places restrictions on certain bulk data transactions involving "Countries of Concern" (China, Hong Kong, Iran, Cuba, Russia, North Korea, and Venezuela) and covered individuals (i.e., individuals and entities located in or controlled by individuals or entities located in those jurisdictions). The Rule's restrictions could significantly impact some of our business activities, such as clinical related vendor engagements and collaborations and partnerships. If there is no lawful manner, including applicable exemptions under the Rule, for us to transfer sensitive personal information of U.S. persons to persons or entities located in Countries of Concern, we may face significant business disruptions, including needing to change our operations by re-locating portions of our business, personnel and/or data processing activities to other jurisdictions (such as the United States) and having to engage with vendors and partners located outside Countries of Concern.
We may be exposed to the risk of employee fraud or other misconduct, including intentional failures to (i) comply with FDA or Office of Inspector General regulations or similar regulations of comparable non-U.S. regulatory authorities, (ii) provide
Paragraphs in the 10-Q filed Nov 4, 2026 that were not in the one before
New in the latest 10-Q
26 paragraphs in the 10-Q filed Nov 4, 2026 with nothing like them in the 10-Q filed Jul 23, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
10-Q
• the effects of AstraZeneca’s (as defined below) ownership and contractual rights on us and our stockholders;
Read in the 10-Q
• our reliance on third parties for the supply of third-party products and other contributions to certain clinical trials involving the combination of ivonescimab with third-party products;
Read in the 10-Q
Financial statements and notes
Subsequent to the quarter ended September 30, 2026, the Company received gross proceeds of $ 2,000,000 from AstraZeneca Holdings B.V, a subsidiary of AstraZeneca plc (together with its subsidiaries, “AstraZeneca”) in connection with the closing of the AstraZeneca Equity Investment (as defined below). For additional detail on the AstraZeneca Equity Investment, refer to Note 10 AstraZeneca Equity Investment. With the AstraZeneca Equity Investment, the Company has evaluated and concluded that its cash, cash equivalents and short-term investments provide sufficient cash to fund its operating cash needs for at least the next 12 months from the date of issuance of these unaudited condensed consolidated financial statements.
Read in the 10-Q
to time through the sales agent under the Distribution Agreement by an additional $ 360,000. As of September 30, 2026, the company fully utilized the proceeds available under the Distribution Agreement.
Read in the 10-Q
The conversion of the Class A Preferred Stock is subject to the expiration and termination of the applicable waiting period of the Hart‑Scott‑Rodino Antitrust Improvements Act of 1976 (“HSR”) and the Company obtaining shareholder approval to amend its certificate of incorporation to increase the number of authorized shares of common stock by 1,000,000,000 (the “Charter Amendment Proposal”). The stockholders of the Company approved the Charter Amendment Proposal on November 4, 2026. The Class A Preferred Stock and the common stock issuable on conversion are subject to a one-year lock-up period after closing.
Read in the 10-Q
Show the other 21
(e) ivonescimab combined with enfortumab vedotin in patients with first-line UC, also known as bladder cancer (“HARMONi-GU1”; Phase II/III); and
Read in the 10-Q
(f) multiple ivonescimab-based combination treatment approaches in patients with incurable locally advanced or metastatic clear cell renal cell carcinoma (“ccRCC”) who have not received prior systemic therapy for advanced disease (“SMT112-216”, also referred to as “AK112-216”; Phase II).
Read in the 10-Q
Based on the results of the HARMONi clinical trial, we submitted a Biologics License Application (“BLA”) in the fourth quarter of 2025 to seek approval for ivonescimab plus chemotherapy for this proposed indication. After careful consideration
Read in the 10-Q
agreed to purchase a certain portion of drug substance and/or drug product for clinical and commercial supply and to enter into a supply agreement with Akeso.
Read in the 10-Q
The conversion of the Class A Preferred Stock is subject to the expiration and termination of the applicable waiting period of HSR and the Company obtaining stockholder approval of the Charter Amendment Proposal. The stockholders of the Company approved the Charter Amendment Proposal on November 4, 2026. The Class A Preferred Stock and the common stock issuable on conversion are subject to a one-year lock-up period after closing.
Read in the 10-Q
In September 2026, the Company entered into a clinical trial collaboration with AstraZeneca to evaluate ivonescimab in combination with AstraZeneca’s Claudin 18.2-targeting antibody-drug conjugate (“ADC”), sonesitatug vedotin, also referred to as sone-ve, in certain gastrointestinal cancer settings (the “AstraZeneca Collaboration”). Each company will contribute their respective compound for the combination studies to be conducted, and the parties will jointly contribute to the costs of such studies, which are intended to be sponsored by AstraZeneca. The AstraZeneca Collaboration does not include upfront payments, milestone payments, or royalty sharing provisions. Each company will retain development and commercial rights to their respective molecules.
Read in the 10-Q
Additionally in September 2026, the Company executed a non-binding memorandum of understanding with AstraZeneca whereby the two companies intend to enter into an agreement to conduct clinical trials combining ivonescimab with multiple AstraZeneca cancer medicines, including AstraZeneca’s leading portfolio of ADCs (the “AstraZeneca MOU”). Pursuant to the AstraZeneca MOU, the companies intend to share clinical development costs of potential future studies. Each company
Read in the 10-Q
will retain their current development and commercial rights to their respective molecules, and the agreement is mutually non-exclusive. The AstraZeneca MOU does not include upfront payments, milestone payments, or royalty sharing provisions.
Read in the 10-Q
In October 2026, the Company entered into a clinical trial collaboration with AstraZeneca and Daiichi Sankyo (“Daiichi”) to evaluate ivonescimab in combination with TROP2-directed ADC, datopotamab deruxtecan (Datroway®), across multiple solid tumor settings, intending to include breast cancer and lung cancer (the “AZDS Collaboration”). The companies intend to begin with a Phase III trial in first-line triple-negative breast cancer (“TNBC”). The Company, and AstraZeneca and Daiichi, will contribute their respective compound for the combination studies to be conducted, and the parties will jointly contribute to the costs of such studies, which will be sponsored by AstraZeneca or Daiichi. The AZDS Collaboration does not include upfront payments, milestone payments, or royalty sharing provisions. The Company, and AstraZeneca and Daiichi, will retain development and commercial rights to their respective molecules.
Read in the 10-Q
On August 5, 2026, the Company announced the expansion of its global registration-enabling clinical development program for ivonescimab into urothelial carcinoma, or bladder cancer, with the planned initiation of the global, multi-regional Phase II/III HARMONi-GU1 trial (“HARMONi-GU1”). HARMONi-GU1 will evaluate ivonescimab plus the antibody-drug conjugate enfortumab vedotin (“EV”) compared to pembrolizumab plus EV as first-line therapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. Global clinical trial site activations for and enrollment in HARMONi-GU1 has begun for the Phase II portion of this study.
Read in the 10-Q
On October 19, 2026, the Company announced the initiation and opening of trial sites for SMT112-216, a global Phase II study of ivonescimab in previously untreated advanced ccRCC. The study, also referred to as AK112-216, is being conducted in collaboration with Summit’s partner, Akeso Inc. SMT112-216 is a randomized, open-label Phase II clinical study designed to evaluate the safety and efficacy of multiple ivonescimab-based treatment approaches in patients with incurable locally advanced or metastatic ccRCC who have not received prior systemic therapy for advanced disease. The study plans to enroll approximately 100 patients at clinical trial sites in the U.S. and China. Participants will be randomized to receive ivonescimab in combination with cadonilimab, ivonescimab in combination with ipilimumab, ivonescimab monotherapy, or
Read in the 10-Q
nivolumab plus ipilimumab as an established standard-of-care comparator regimen. Cadonilimab is an investigational PD-1 / CTLA-4 bispecific antibody developed by Akeso. This study is in addition to Summit’s clinical trial collaboration with Arcus evaluating ivonescimab in combination with casdatifan, a HIF2α inhibitor, in a similar ccRCC setting.
Read in the 10-Q
Cooperative Group-Sponsored Phase III Clinical Studies (Summit’s License Territories)
Read in the 10-Q
In the fourth quarter of 2026, the Company announced a clinical collaboration with ECOG-ACRIN Cancer Research Group (“ECOG-ACRIN”), a scientific organization focused on innovative multicenter clinical trials, to initiate the registration-enabling Phase II/III clinical study, EA2251 (NCT07765433), evaluating ivonescimab in combination with chemotherapy compared to pembrolizumab or durvalumab in combination with chemotherapy in advanced biliary tract cancer (“BTC”). Sponsored by ECOG-ACRIN, the primary endpoint for the study is OS. Activation of U.S. clinical trial sites is expected to begin in the fourth quarter of 2026. Data supporting EA2251 was previously presented at ESMO 2026 via HARMONi-GI1, a single-region Phase III study from China sponsored by Akeso, which is further described below.
Read in the 10-Q
On September 13, 2026, detailed clinical trial results of the HARMONi-2 study, including interim OS, were presented as part of the Presidential Symposium at WCLC 2026. In this protocol-specified interim analysis of OS, a secondary endpoint in
Read in the 10-Q
the HARMONi-2 study, ivonescimab monotherapy demonstrated a statistically significant and clinically meaningful improvement compared to pembrolizumab monotherapy, achieving a hazard ratio of 0.73 (95% CI: 0.57, 0.95; p=0.009). A clinically meaningful benefit was demonstrated across important clinical subgroups, including those with PD-L1 low expression (PD-L1 Score 1-49%) and PD-L1 high expression (PD-L1 Score ≥ 50%), along with those with squamous and non-squamous histologies. In this analysis, ivonescimab continued to demonstrate an acceptable and manageable safety profile in the HARMONi-2 study, which was consistent with previous Phase III studies of ivonescimab. No additional safety signals were noted in the HARMONi-2 study in this current data cut with longer treatment duration (median of 14 cycles of ivonescimab vs. 10 cycles of pembrolizumab) compared to the previous data cut.
Read in the 10-Q
In August 2026, Akeso announced receipt of marketing authorization in China from the NMPA for the use of ivonescimab, in combination with chemotherapy for the first-line treatment of patients with advanced squamous NSCLC.
Read in the 10-Q
ivonescimab plus chemotherapy, compared to 50.7% and 32.5%, respectively, for those receiving durvalumab plus chemotherapy. Median follow-up time of the current data cut was 14.3 months.
Read in the 10-Q
Subsequent to the quarter ended September 30, 2026, the Company received gross proceeds of $2.0 billion from AstraZeneca in connection with the closing of the AstraZeneca Equity Investment. With the AstraZeneca Equity Investment, the Company has evaluated and concluded that its cash, cash equivalents and short-term investments provide sufficient cash to fund its operating cash needs for at least the next 12 months from the date of issuance of these condensed consolidated financial statements.
Read in the 10-Q
Other information
On November 4, 2026, the Company entered into the 2026 Sublease Agreement with Genius, an affiliate of the Company’s Co-CEO, Robert W. Duggan. Pursuant to the 2026 Genius Sublease Agreement, effective November 1, 2026, the Company sublet from Genius 2,382 square feet of office space in the same facility as the Company’s headquarters in Miami, Florida for a twelve month term for a total rental payment of approximately $205.
Read in the 10-Q
Item 6
Certain of the exhibits and schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.
Read in the 10-Q
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Nov 4, 2026 against Item 1A of the 10-K filed Feb 23, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted).
Text on the page, not a score; each links to the filing at sec.gov.
What the 10-Q itself says about its risk factors:There have been no material changes to the risk factors disclosed in Item 1A of our Annual Report.
Read in the 10-Q
Phrases used for the first time
Two-word phrases in Risk Factors of the 10-K filed Feb 23, 2026 that are in none of the 1 earlier 10-Ks stored, back to Feb 24, 2025
Where each one is used
- foreign regulatory: We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
- medicare part: Other legislative changes have been proposed and adopted since passage of the ACA. These have, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover...
- comparable foreign: We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
- chinese biotechnology: In addition, certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements, or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting the supply of material...
- mfn pricing: The current administration is pursuing policies to reduce regulations and expenditures across government including at HHS, which include the FDA and CMS, and related agencies. For example, on May 12, 2025, President Trump issued an Executive Order that, among other things, required HHS, within 30 days, to establish...
- accept data: We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
- medical practice: We have conducted, and may in the future conduct, clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials. We are currently conducting clinical trials in China, and we expect to continue to...
- negotiated prices: Other legislative changes have been proposed and adopted since passage of the ACA. These have, among other things, reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover...
Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.
What was taken out
24 paragraphs of last year's Risk Factors with nothing like them now. The longest are quoted.
Sources
Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.
Also
10-K change: what was reworded or cut, section by section.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SMMT/export.csv") into a cell.